2024
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchConceptsRandomized phase II trialCD4/CD8 T cellsT cellsHPV clearanceArm BNo significant differenceClinical surveillanceRate of HPV clearanceSecondary outcomesPre-neoplastic cervical lesionsCervical intraepithelial neoplasiaT cell infiltrationT cell responsesSignificant differenceCIN3 patientsIntraepithelial neoplasiaArm ACervical lesionsImiquimod groupSurveillance armVaginal suppositoriesProspective trialsArm CHPV vaccinationImiquimod
2023
Human Papillomavirus Vaccination Status and Correlates Among Mid-Adult Women: Connecticut, USA, 2016–2019
Sheth S, Johnson N, Sullivan E, Torres A, Oliveira C, Niccolai L. Human Papillomavirus Vaccination Status and Correlates Among Mid-Adult Women: Connecticut, USA, 2016–2019. Journal Of Women's Health 2023, 33: 28-32. PMID: 37943625, PMCID: PMC10794823, DOI: 10.1089/jwh.2022.0456.Peer-Reviewed Original ResearchConceptsMid-adult womenVaccination statusHPV vaccinationHPV vaccineHuman Papillomavirus Vaccination StatusHPV vaccination statusHuman papillomavirus vaccinationAge 26 yearsHealth care providersCross-sectional surveyPapillomavirus vaccinationUnvaccinated womenVaccinated womenVaccine informationCare providersVaccinationAdult womenVaccineWomenBehavioral correlatesCorrelatesStatusPotential benefitsYearsParticipants